

Dimos-Dimitrios D Mitsikostas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4641554/dimos-dimitrios-d-mitsikostas-publications-by-year.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

241 papers	19,318 citations	60 h-index	137 g-index
262 ext. papers	22,184 ext. citations	6.5 avg, IF	7.8 L-index

#	Paper	IF	Citations
241	Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.. <i>Journal of Neurology</i> , 2022 , 1	5.5	0
240	Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review. <i>Lancet Regional Health - Europe, The</i> , 2022 , 12, 100253		14
239	COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. <i>Rheumatology International</i> , 2021 , 42, 31	3.6	9
238	Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers. <i>Vaccines</i> , 2021 , 9,	5.3	2
237	Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	1
236	Validity and reliability of the Greek version of the neurogenic bladder symptom score (NBSS) questionnaire in a sample of Greek patients with multiple sclerosis. <i>World Journal of Urology</i> , 2021 , 39, 2697-2702	4	3
235	Tension-type headache. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 24	51.1	25
234	An updated brief overview on post-traumatic headache and a systematic review of the non-pharmacological interventions for its management. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 475-490	4.3	1
233	Migraine: integrated approaches to clinical management and emerging treatments. <i>Lancet, The</i> , 2021 , 397, 1505-1518	40	34
232	Current advances in the management of cluster headaches. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1931-1943	4	1
231	Diagnosis and management of migraine in ten steps. <i>Nature Reviews Neurology</i> , 2021 , 17, 501-514	15	33
230	Safety and tolerability evaluation of erenumab for the preventive treatment of migraine. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 867-876	4.1	3
229	Structured Q1 headache services as the solution to the ill-health burden of headache: 1. Rationale and description. <i>Journal of Headache and Pain</i> , 2021 , 22, 78	8.8	14
228	Nocebo phenomena may be enhanced in aging: Implications for clinical practice. <i>Maturitas</i> , 2021 , 143, 10-16	5	2
227	Making headway - a role for CGRP in post-traumatic headache. <i>Nature Reviews Neurology</i> , 2021 , 17, 133-134	13.4	2
226	B3 agonists or anticholinergics in the treatment of the lower urinary tract dysfunction in patients with multiple sclerosis?-A randomized study. <i>World Journal of Urology</i> , 2021 , 39, 3049-3056	4	1
225	Monoclonal Antibodies as Neurological Therapeutics. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	12

224	A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study. <i>Advances in Therapy</i> , 2021 , 38, 1536-1551	4.1	1
223	A population-based survey for disabling headaches in Greece: Prevalence, burden and treatment preferences. <i>Cephalalgia</i> , 2021 , 41, 810-820	6.1	2
222	Shared biological foundations of post-traumatic headache and migraine. <i>Headache</i> , 2021 , 61, 558-559	4.2	2
221	Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. <i>Cephalalgia</i> , 2021 , 41, 851-864	6.1	12
220	Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	4
219	Peak Activation Shifts in the Sensorimotor Cortex of Chronic Stroke Patients Following Robot-assisted Rehabilitation Therapy. <i>Open Neuroimaging Journal</i> , 2021 , 14, 8-15	0.1	
218	Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects. <i>Current Medical Research and Opinion</i> , 2021 , 37, 1761-1768	2.5	1
217	Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions. <i>Journal of Headache and Pain</i> , 2021 , 22, 90	8.8	10
216	Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology. <i>Journal of Headache and Pain</i> , 2021 , 22, 99	8.8	8
215	Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	3
214	PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine. <i>Pain Management</i> , 2021 , 11, 647-654	2.3	1
213	Galcanzumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420918088	6.6	10
212	Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , 2020 , 9, 443-457	4.6	4
211	Is There a Brain/Heart Interaction in Rheumatoid Arthritis and Seronegative Spondyloarthropathies? A Combined Brain/Heart Magnetic Resonance Imaging Reveals the Answer. <i>Current Rheumatology Reports</i> , 2020 , 22, 39	4.9	1
210	Extra-Axial Inflammatory Signal in Parameninges in Migraine with Visual Aura. <i>Annals of Neurology</i> , 2020 , 87, 939-949	9.4	24
209	Current understanding and future perspectives of brain-heart-kidney axis in psoriatic arthritis. <i>Rheumatology International</i> , 2020 , 40, 1361-1368	3.6	1
208	Aging, Cellular Senescence, and Progressive Multiple Sclerosis. <i>Frontiers in Cellular Neuroscience</i> , 2020 , 14, 178	6.1	18
207	Acute sleep deprivation enhances susceptibility to the migraine substrate cortical spreading depolarization. <i>Journal of Headache and Pain</i> , 2020 , 21, 86	8.8	12

206	Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. <i>Journal of Neurology</i> , 2020 , 267, 3343-3353	5.5	13
205	Combined Brain-Heart Magnetic Resonance Imaging in Autoimmune Rheumatic Disease Patients with Cardiac Symptoms: Hypothesis Generating Insights from a Cross-sectional Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
204	352. Seronegative Relapse of Brucellosis in the Central Nervous System. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S245-S245	1	
203	Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic. <i>Mediterranean Journal of Rheumatology</i> , 2020 , 31, 288-294	1.4	6
202	Definition of Refractory Chronic Headache. <i>Headache</i> , 2020 , 33-40	0.2	
201	AB0553 THE NOCEBO PHENOMENON PARTLY ACCOUNTS FOR DIARRHOEA AMONG PARTICIPANTS IN THE RANDOMIZED PLACEBO-CONTROLLED TRIAL OF NINTEDANIB FOR INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS (SENSCIS). <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1553-1553	2.4	
200	Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis. <i>Journal of Neurology</i> , 2020 , 267, 1158-1170	5.5	9
199	Lateralization of Insular Ischemic Stroke is Not Associated With Any Stroke Clinical Outcomes: The Athens Stroke Registry. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020 , 29, 104529	2.8	1
198	Analysis of HCRTR2, GNB3, and ADH4 Gene Polymorphisms in a Southeastern European Caucasian Cluster Headache Population. <i>Journal of Molecular Neuroscience</i> , 2020 , 70, 467-474	3.3	7
197	European Headache Federation recommendations for placebo and nocebo terminology. <i>Journal of Headache and Pain</i> , 2020 , 21, 117	8.8	9
196	IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naïve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Advances in Therapy</i> , 2020 , 37, 4249-4265	4.1	2
195	Safety, Tolerability, and Nocebo Phenomena During Transcranial Magnetic Stimulation: A Systematic Review and Meta-Analysis of Placebo-Controlled Clinical Trials. <i>Neuromodulation</i> , 2020 , 23, 291-300	3.1	26
194	Availability of Effective Evidence-Based Symptomatic Treatments for Cluster Headache in the EU Countries-A Survey of the European Headache Alliance and European Headache Federation. <i>Journal of Oral and Facial Pain and Headache</i> , 2020 , 34, 7-12	2.5	2
193	Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. <i>Cephalalgia</i> , 2019 , 39, 1475-1487	6.1	35
192	Migraine and the trigeminovascular system-40 years and counting. <i>Lancet Neurology</i> , 2019 , 18, 795-804	8.4	114
191	Headache service quality: the role of specialized headache centres within structured headache services, and suggested standards and criteria as centres of excellence. <i>Journal of Headache and Pain</i> , 2019 , 20, 24	8.8	15
190	Nocebo in Headache Treatment. <i>Headache</i> , 2019 , 75-84	0.2	
189	Nocebo in Biosimilars and Generics in Neurology: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2019 , 10, 809	5.6	5

188	Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece. <i>Clinical Drug Investigation</i> , 2019 , 39, 979-990	3.2	12
187	Nocebo in multiple sclerosis trials: A meta-analysis on oral and newer injectable disease-modifying treatments. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 36, 101389	4	4
186	Trigeminal-Targeted Treatments in Migraine: Is 60% the Magic Number?. <i>Headache</i> , 2019 , 59, 1659-1661	4.2	6
185	Headaches in the emergency department -a survey of patientsPcharacteristics, facts and needs. <i>Journal of Headache and Pain</i> , 2019 , 20, 100	8.8	19
184	AuthorsPReply to Tsivgoulis et al.: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A likelihood to Achieve No Evidence of Disease Activity or Harm Analysis". <i>CNS Drugs</i> , 2019 , 33, 297-298	6.7	
183	Glucocorticoids Regulate Bone Marrow B Lymphopoiesis After Stroke. <i>Circulation Research</i> , 2019 , 124, 1372-1385	15.7	26
182	Implications of Placebos and Nocebos in Clinical Practice. <i>Headache</i> , 2019 , 125-134	0.2	
181	Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine. <i>Journal of Headache and Pain</i> , 2019 , 20, 113	8.8	13
180	European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. <i>Journal of Headache and Pain</i> , 2019 , 20, 6	8.8	158
179	Vascular dysfunction-The disregarded partner of AlzheimerB disease. <i>Alzheimerls and Dementia</i> , 2019 , 15, 158-167	1.2	265
178	Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. <i>Cephalalgia</i> , 2019 , 39, 608-616	6.1	12
177	Caffeine does not affect susceptibility to cortical spreading depolarization in mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019 , 39, 740-750	7.3	8
176	Reducing myeloperoxidase activity decreases inflammation and increases cellular protection in ischemic stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019 , 39, 1864-1877	7.3	15
175	20-year trends of characteristics and outcomes of stroke patients with atrial fibrillation. <i>International Journal of Stroke</i> , 2018 , 13, 707-716	6.3	6
174	Reply to Tsivgoulis and colleagues comments. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 21, 120-121	4	1
173	Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials. <i>Journal of the Neurological Sciences</i> , 2018 , 388, 79-83	3.2	13
172	Novel candidate genes of the PARK7 interactome as mediators of apoptosis and acetylation in multiple sclerosis: An in silico analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 19, 8-14	4	6
171	Population-Based Analysis of Cluster Headache-Associated Genetic Polymorphisms. <i>Journal of Molecular Neuroscience</i> , 2018 , 65, 367-376	3.3	8

170	Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis. <i>CNS Drugs</i> , 2018 , 32, 1069-1078	6.7	4
169	Nocebo Responses in Brain Diseases: A Systematic Review of the Current Literature. <i>International Review of Neurobiology</i> , 2018 , 139, 443-462	4.4	13
168	Neuroprotection Mediated by Upregulation of Endothelial Nitric Oxide Synthase in Rho-Associated, Coiled-Coil-Containing Kinase 2 Deficient Mice. <i>Circulation Journal</i> , 2018 , 82, 1195-1204	2.9	9
167	Value of treatment of headache patients and need to improve headache patients' journey. <i>Neurological Sciences</i> , 2018 , 39, 115-116	3.5	4
166	Recommendations for Mechanical Thrombectomy in Patients with Acute Ischemic Stroke : A Clinical Guide by the Hellenic Stroke Organization. <i>Clinical Neuroradiology</i> , 2018 , 28, 145-151	2.7	3
165	Male and female sex hormones in primary headaches. <i>Journal of Headache and Pain</i> , 2018 , 19, 117	8.8	56
164	Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. <i>Journal of Headache and Pain</i> , 2018 , 19, 91	8.8	64
163	Nocebos in rheumatology: emerging concepts and their implications for clinical practice. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 727-740	8.1	47
162	Variables affecting factors associated with primary headache. <i>Clinics and Practice</i> , 2018 , 8, 1031	2.4	1
161	Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). <i>Journal of Headache and Pain</i> , 2018 , 19, 76	8.8	34
160	Inhibition of the P2X7-PANX1 complex suppresses spreading depolarization and neuroinflammation. <i>Brain</i> , 2017 , 140, 1643-1656	11.2	60
159	Functional Anatomy of Trigemino-vascular Pain 2017 , 1-29		
158	Lessons Learned from CGRP Mutant Mice 2017 , 175-188		1
157	The Clinical Characteristics of Migraine 2017 , 189-200		
156	The Premonitory Phase of Migraine 2017 , 201-208		
155	The Genetic Borderland of Migraine and Epilepsy 2017 , 209-231		
154	Genetics of Monogenic and Complex Migraine 2017 , 233-250		
153	Lessons from Familial Hemiplegic Migraine and Cortical Spreading Depression 2017 , 251-265		2

152	Mathematical Modeling of Human Cortical Spreading Depression 2017 , 285-305		
151	Tools for High-Resolution in vivo Imaging of Cellular and Molecular Mechanisms in Cortical Spreading Depression and Spreading Depolarization 2017 , 307-320		
150	Animal Models of Migraine Aura 2017 , 321-345		1
149	Physiology of the Meningeal Sensory Pathway 2017 , 31-47		
148	Human Models of Migraine 2017 , 347-362		
147	Imaging Pain and Headache 2017 , 363-376		
146	Meningeal Afferent Ion Channels and their Role in Migraine 2017 , 49-68		0
145	Functional Architecture of Central Pain Pathways: Focus on the Trigeminovascular System 2017 , 69-90		
144	Visceral Pain 2017 , 91-106		
143	Meningeal Neurogenic Inflammation and Dural Mast Cells in Migraine Pain 2017 , 107-123		
142	Sensitization and Photophobia in Migraine 2017 , 125-138		
141	Central Circuits Promoting Chronification of Migraine 2017 , 139-155		
140	Triptans to Calcitonin Gene-Related Peptide Modulators [Small Molecules to Antibodies] The Evolution of a New Migraine Drug Class 2017 , 157-174		
139	Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017 , 18, 576-582	3.6	12
138	Holes in the leaky migraine blood-brain barrier hypothesis?. <i>Brain</i> , 2017 , 140, 1537-1539	11.2	2
137	Refractory burning mouth syndrome: clinical and paraclinical evaluation, comorbiities, treatment and outcome. <i>Journal of Headache and Pain</i> , 2017 , 18, 40	8.8	14
136	Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. <i>Current Opinion in Neurology</i> , 2017 , 30, 272-280	7.1	58
135	Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: Systematic review and meta-analysis of placebo-controlled clinical trials. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2017 , 45, 95-99	3.2	22

134	Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). <i>Journal of Headache and Pain</i> , 2017 , 18, 108	8.8	91
133	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. <i>Lancet Neurology</i> , 2017 , 16, 976-986	24.1	278
132	Patients' preferences for headache acute and preventive treatment. <i>Journal of Headache and Pain</i> , 2017 , 18, 102	8.8	28
131	Comparing the efficacy of disease-modifying therapies in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 18, 109-116	4	17
130	Convexity Subarachnoid Hemorrhage Due to Cardioembolic Stroke in a Woman with Thyrotoxicosis: Case Report. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017 , 26, e195-e196	2.8	2
129	Headache and pregnancy: a systematic review. <i>Journal of Headache and Pain</i> , 2017 , 18, 106	8.8	89
128	Myeloperoxidase Inhibition Increases Neurogenesis after Ischemic Stroke. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016 , 359, 262-272	4.7	31
127	Placebo and Nocebo Effects. <i>Headache</i> , 2016 , 56, 31-43	0.2	1
126	Nocebo in headache. <i>Current Opinion in Neurology</i> , 2016 , 29, 331-6	7.1	16
125	Onabotulinumtoxin-A treatment in Greek patients with chronic migraine. <i>Journal of Headache and Pain</i> , 2016 , 17, 84	8.8	18
124	Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation. <i>Neurological Sciences</i> , 2015 , 36, 379-81	3.5	19
123	Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important. <i>Internal and Emergency Medicine</i> , 2015 , 10, 413-21	3.7	17
122	Supply-demand mismatch transients in susceptible peri-infarct hot zones explain the origins of spreading injury depolarizations. <i>Neuron</i> , 2015 , 85, 1117-31	13.9	120
121	Nocebo in Alzheimer's disease; meta-analysis of placebo-controlled clinical trials. <i>Journal of the Neurological Sciences</i> , 2015 , 355, 94-100	3.2	23
120	Update on Medication-Overuse Headache and Its Treatment. <i>Current Treatment Options in Neurology</i> , 2015 , 17, 368	4.4	11
119	Ischemic stroke activates hematopoietic bone marrow stem cells. <i>Circulation Research</i> , 2015 , 116, 407-17	15.7	126
118	European Headache Federation consensus on technical investigation for primary headache disorders. <i>Journal of Headache and Pain</i> , 2015 , 17, 5	8.8	66
117	Neck pain in episodic migraine: premonitory symptom or part of the attack?. <i>Journal of Headache and Pain</i> , 2015 , 16, 566	8.8	57

116	New players in the preventive treatment of migraine. <i>BMC Medicine</i> , 2015 , 13, 279	11.4	32
115	Myeloperoxidase propagates damage and is a potential therapeutic target for subacute stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015 , 35, 485-93	7.3	40
114	Headache in Systemic Diseases. <i>Headache</i> , 2015 , 229-234	0.2	
113	Nocebo in clinical trials for depression: a meta-analysis. <i>Psychiatry Research</i> , 2014 , 215, 82-6	9.9	55
112	Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 375-85	5.9	17
111	Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations. <i>Nature Reviews Neuroscience</i> , 2014 , 15, 379-93	13.5	226
110	Natalizumab-related progressive multifocal leukoencephalopathy in Greece. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 203-10	4	2
109	Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation. <i>Journal of Headache and Pain</i> , 2014 , 15, 79	8.8	69
108	Lupus headache may not exist: comment on the article by Hanly et Al. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1058	9.5	4
107	Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. <i>Pain Management</i> , 2014 , 4, 123-8	2.3	5
106	Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. <i>Journal of Headache and Pain</i> , 2014 , 15, 47	8.8	72
105	The International Classification of Headache Disorders, 3rd edition (beta version). <i>Cephalalgia</i> , 2013 , 33, 629-808	6.1	5503
104	Treating primary headaches [management of migraine. <i>Journal of Headache and Pain</i> , 2013 , 14,	8.8	78
103	Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis. <i>European Journal of Neurology</i> , 2013 , 20, 527-533	6	44
102	Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. <i>European Journal of Neurology</i> , 2012 , 19, 672-80	6	64
101	TNFR2 on non-haematopoietic cells is required for Foxp3+ Treg-cell function and disease suppression in EAE. <i>European Journal of Immunology</i> , 2012 , 42, 403-12	6.1	40
100	A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. <i>Journal of Neurology</i> , 2012 , 259, 436-47	5.5	72
99	Nocebo in headaches: implications for clinical practice and trial design. <i>Current Neurology and Neuroscience Reports</i> , 2012 , 12, 132-7	6.6	36

98	Depression in headaches: chronification. <i>Current Opinion in Neurology</i> , 2012 , 25, 277-83	7.1	13
97	Targeting to 5-HT _{1F} receptor subtype for migraine treatment: lessons from the past, implications for the future. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2012 , 12, 241-9	1.8	20
96	Sumatriptan transdermal iontophoretic patch (NP101-Zelrix®) review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. <i>Neuropsychiatric Disease and Treatment</i> , 2012 , 8, 429-34	3.1	20
95	Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. <i>European Journal of Neurology</i> , 2011 , 18, 556-63	6	40
94	Headache in systemic lupus erythematosus vs multiple sclerosis: a prospective comparative study. <i>Headache</i> , 2011 , 51, 1398-407	4.2	26
93	Triptans attenuate capsaicin-induced CREB phosphorylation within the trigeminal nucleus caudalis: a mechanism to prevent central sensitization?. <i>Journal of Headache and Pain</i> , 2011 , 12, 411-7	8.8	15
92	Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. <i>Cephalalgia</i> , 2011 , 31, 550-61	6.1	99
91	Nocebo effects in multiple sclerosis trials: a meta-analysis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 816-28	5	54
90	Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial. <i>Cephalalgia</i> , 2010 , 30, 690-5	6.1	3
89	Brain protection: maybe yes, maybe no. <i>Stroke</i> , 2010 , 41, S85-6	6.7	26
88	Migraine general aspects. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2010 , 97, 253-66	3	10
87	The science of stroke: mechanisms in search of treatments. <i>Neuron</i> , 2010 , 67, 181-98	13.9	1329
86	Apraxia related with subcortical lesions due to cerebrovascular disease. <i>Acta Neurologica Scandinavica</i> , 2010 , 122, 9-14	3.8	7
85	The existence of phonatory instability in multiple sclerosis: an acoustic and electroglottographic study. <i>Neurological Sciences</i> , 2010 , 31, 259-68	3.5	20
84	Guidelines for the organization of headache education in Europe: the headache school II. <i>Journal of Headache and Pain</i> , 2010 , 11, 161-5	8.8	7
83	EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. <i>European Journal of Neurology</i> , 2010 , 17, 1318-25	6	228
82	Sleep and headache: the clinical relationship. <i>Headache</i> , 2010 , 50, 1233-45	4.2	11
81	An observational trial to investigate the efficacy and tolerability of levetiracetam in trigeminal neuralgia. <i>Headache</i> , 2010 , 50, 1371-7	4.2	21

80	Androgenic suppression of spreading depression in familial hemiplegic migraine type 1 mutant mice. <i>Annals of Neurology</i> , 2009 , 66, 564-8	9.4	79
79	Headaches in antiquity and during the early scientific era. <i>Journal of Neurology</i> , 2009 , 256, 1215-20	5.5	25
78	Defining a pathway to discovery from bench to bedside: the trigeminovascular system and sensitization. <i>Headache</i> , 2008 , 48, 688-90	4.2	39
77	Refractory chronic headache associated with obstructive sleep apnoea syndrome. <i>Cephalalgia</i> , 2008 , 28, 139-43	6.1	48
76	Animal models of migraine headache and aura. <i>Current Opinion in Neurology</i> , 2008 , 21, 294-300	7.1	36
75	Cortical spreading depression and estrogen. <i>Headache</i> , 2007 , 47 Suppl 2, S79-85	4.2	31
74	A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. <i>Cephalalgia</i> , 2007 , 27, 315-24	6.1	71
73	The 2006 Thomas Willis lecture: the adventures of a translational researcher in stroke and migraine. <i>Stroke</i> , 2007 , 38, 1645-51	6.7	7
72	Genes, proteases, cortical spreading depression and migraine: impact on pathophysiology and treatment. <i>Functional Neurology</i> , 2007 , 22, 133-6	2.2	41
71	Suppression of cortical spreading depression in migraine prophylaxis. <i>Annals of Neurology</i> , 2006 , 59, 652-61	9.4	440
70	Animal models of migraine: looking at the component parts of a complex disorder. <i>European Journal of Neuroscience</i> , 2006 , 24, 1517-34	3.5	101
69	Add-on topiramate in the treatment of refractory partial-onset epilepsy: clinical experience of outpatient epilepsy clinics from 11 general hospitals. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2005 , 14, 396-402	3.2	7
68	Time perception in migraine sufferers: an experimental matched-pairs study. <i>Cephalalgia</i> , 2005 , 25, 60-76.1	6.1	11
67	SUNCT syndrome in the elderly. <i>Cephalalgia</i> , 2005 , 25, 1091-2	6.1	13
66	Cortical Spreading Depression: A Model for Understanding Migraine Biology and Future Drug Targets. <i>Headache Currents: A Journal for Recent Advances in Headache and Facial Pain</i> , 2005 , 2, 97-103		22
65	Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. <i>Annals of Neurology</i> , 2004 , 55, 276-80	9.4	185
64	A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. <i>Brain</i> , 2004 , 127, 1200-9	11.2	110
63	5-Hydroxytryptamine(1B/1D) and 5-hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse trigeminal nucleus caudalis. <i>Cephalalgia</i> , 2002 , 22, 384-94	6.1	26

62 Central nervous system ischemia: diversity among the caspases **2002**, 9-20

61 Regional sensitivity and coupling of BOLD and CBV changes during stimulation of rat brain. *Magnetic Resonance in Medicine*, **2001**, 45, 443-7 4.4 116

60 Dynamic imaging of cerebral blood flow using laser speckle. *Journal of Cerebral Blood Flow and Metabolism*, **2001**, 21, 195-201 7.3 609

59 Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine. *Brain Research Reviews*, **2001**, 35, 20-35 86

58 Evidence for apoptosis after intercerebral hemorrhage in rat striatum. *Journal of Cerebral Blood Flow and Metabolism*, **2000**, 20, 396-404 7.3 230

57 Comorbidity of headache and depressive disorders. *Cephalalgia*, **1999**, 19, 211-7 6.1 163

56 Perfusion weighted imaging during migraine: spontaneous visual aura and headache. *Cephalalgia*, **1999**, 19, 701-7 6.1 172

55 Attenuation by butalbital of capsaicin-induced c-fos-like immunoreactivity in trigeminal nucleus caudalis. *Headache*, **1999**, 39, 697-704 4.2 16

54 Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. *British Journal of Pharmacology*, **1999**, 127, 623-30 8.6 60

53 Evidence of a cerebrovascular postarteriole windkessel with delayed compliance. *Journal of Cerebral Blood Flow and Metabolism*, **1999**, 19, 679-89 7.3 426

52 Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. *European Journal of Pharmacology*, **1999**, 369, 271-7 5.3 65

51 Caspases as treatment targets in stroke and neurodegenerative diseases. *Annals of Neurology*, **1999**, 45, 421-9 9.4 288

50 Investigation of the early response to rat forepaw stimulation. *Magnetic Resonance in Medicine*, **1999**, 41, 247-52 4.4 75

49 MRI measurement of the temporal evolution of relative CMRO(2) during rat forepaw stimulation. *Magnetic Resonance in Medicine*, **1999**, 42, 944-51 4.4 194

48 Investigation of the early response to rat forepaw stimulation **1999**, 41, 247 1

47 Synergistic effects of caspase inhibitors and MK-801 in brain injury after transient focal cerebral ischaemia in mice. *British Journal of Pharmacology*, **1998**, 124, 756-62 8.6 135

46 Perfusion-weighted imaging defects during spontaneous migrainous aura. *Annals of Neurology*, **1998**, 43, 25-31 9.4 267

45 Fasciculation potentials in healthy people. *Muscle and Nerve*, **1998**, 21, 533-5 3.4 29

44	Measurement of changes in cerebral blood volume in spontaneously hypertensive rats following L-arginine infusion using dynamic susceptibility contrast MRI. <i>Magnetic Resonance in Medicine</i> , 1998 , 39, 160-3	4.4	8
43	The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. <i>Pain</i> , 1998 , 76, 239-48	8	89
42	Buspirone vs amitriptyline in the treatment of chronic tension-type headache. <i>Acta Neurologica Scandinavica</i> , 1997 , 96, 247-51	3.8	24
41	Primary afferent neurons innervating guinea pig dura. <i>Journal of Neurophysiology</i> , 1997 , 77, 299-308	3.2	86
40	Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a mutant ICE inhibitory protein. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997 , 17, 370-5	7.3	219
39	Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. <i>Nature</i> , 1997 , 390, 622-5	50.4	746
38	Neuronal nitric oxide synthase mutant mice show smaller infarcts and attenuated apparent diffusion coefficient changes in the peri-infarct zone during focal cerebral ischemia. <i>Magnetic Resonance in Medicine</i> , 1997 , 37, 170-5	4.4	54
37	GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. <i>British Journal of Pharmacology</i> , 1996 , 117, 99-104	8.6	66
36	Neuropeptide Y Y2 receptor-mediated attenuation of neurogenic plasma extravasation acting through pertussis toxin-sensitive mechanisms. <i>British Journal of Pharmacology</i> , 1996 , 119, 229-32	8.6	9
35	The effect of sumatriptan on brain monoamines in rats. <i>Headache</i> , 1996 , 36, 29-31	4.2	11
34	The prevalence of headache in Greece: correlations to latitude and climatological factors. <i>Headache</i> , 1996 , 36, 168-73	4.2	41
33	Two more secondary headaches mimicking chronic paroxysmal hemicrania. Is this the exception or the rule?. <i>Headache</i> , 1996 , 36, 511-3	4.2	26
32	An epidemiological study of headaches among medical students in Athens. <i>Headache</i> , 1996 , 36, 561-4	4.2	37
31	Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. <i>Headache</i> , 1996 , 36, 579-85	4.2	99
30	Temporal correlation mapping analysis of the hemodynamic penumbra in mutant mice deficient in endothelial nitric oxide synthase gene expression. <i>Stroke</i> , 1996 , 27, 1381-5	6.7	82
29	Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. <i>British Journal of Pharmacology</i> , 1995 , 116, 3199-204	8.6	65
28	Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. <i>British Journal of Pharmacology</i> , 1995 , 116, 1661-7	8.6	66
27	Autoradiographic visualisation of [3H]5-carboxamidotryptamine binding sites in the guinea pig and rat brain. <i>European Journal of Pharmacology</i> , 1995 , 283, 31-46	5.3	55

26	Suppression by the sumatriptan analogue, CP-122,288 of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. <i>British Journal of Pharmacology</i> , 1995 , 114, 987-92	8.6	28
25	The complex role of nitric oxide in the pathophysiology of focal cerebral ischemia. <i>Brain Pathology</i> , 1994 , 4, 49-57	6	140
24	The valproate mechanisms of action in migraine. <i>Cephalalgia</i> , 1994 , 14, 465	6.1	
23	Pretreatment with intraventricular basic fibroblast growth factor decreases infarct size following focal cerebral ischemia in rats. <i>Annals of Neurology</i> , 1994 , 35, 451-7	9.4	146
22	Cerebral blood flow changes during cortical spreading depression are not altered by inhibition of nitric oxide synthesis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1994 , 14, 939-43	7.3	35
21	An epidemiological study of headache among the Monks of Athos (Greece). <i>Headache</i> , 1994 , 34, 539-41	4.2	19
20	Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. <i>British Journal of Pharmacology</i> , 1994 , 112, 920-4	8.6	56
19	Time-dependent blockade of neurogenic plasma extravasation in dura mater by 5-HT1B/D agonists and endopeptidase 24.11. <i>British Journal of Pharmacology</i> , 1993 , 108, 331-5	8.6	29
18	The effects of valproate in brain monoamines of juvenile rats after stress. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1993 , 17, 295-310	5.5	12
17	L-arginine dilates rat pial arterioles by nitric oxide-dependent mechanisms and increases blood flow during focal cerebral ischaemia. <i>British Journal of Pharmacology</i> , 1992 , 107, 905-7	8.6	100
16	CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. <i>British Journal of Pharmacology</i> , 1992 , 106, 409-15	8.6	105
15	Evidence for the presence of 5-HT1B receptor messenger RNA in neurons of the rat trigeminal ganglia. <i>European Journal of Pharmacology</i> , 1992 , 227, 357-9		45
14	Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater. <i>British Journal of Pharmacology</i> , 1991 , 103, 1421-8	8.6	85
13	CP-93,129, a potent and selective 5-HT1B receptor agonist blocks neurogenic plasma extravasation within rat but not guinea-pig dura mater. <i>British Journal of Pharmacology</i> , 1991 , 104, 3-4	8.6	41
12	Subarachnoid blood and headache: altered trigeminal tachykinin gene expression. <i>Annals of Neurology</i> , 1989 , 25, 179-84	9.4	26
11	Cluster headache: evidence for a pathophysiologic focus in the superior pericarotid cavernous sinus plexus. <i>Headache</i> , 1988 , 28, 584-6	4.2	117
10	Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. <i>Annals of Neurology</i> , 1988 , 24, 732-7	9.4	154
9	Trigeminal origin of beta-preprotachykinin products in feline pial blood vessels. <i>Neuroscience Letters</i> , 1987 , 76, 69-73	3.3	27

8	The neurotoxic effect of gold sodium thiomalate on the peripheral nerves of the rat. Insights into the antiinflammatory actions of gold therapy. <i>Arthritis and Rheumatism</i> , 1986 , 29, 897-901		18
7	Experimental studies on the sensory innervation of the cerebral blood vessels. <i>Cephalalgia</i> , 1986 , 6 Suppl 4, 63-6	6.1	9
6	Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry. <i>Journal of Comparative Neurology</i> , 1984 , 223, 46-56	3.4	302
5	Co-localization of retrogradely transported wheat germ agglutinin and the putative neurotransmitter substance P within trigeminal ganglion cells projecting to cat middle cerebral artery. <i>Journal of Comparative Neurology</i> , 1984 , 225, 187-92	3.4	93
4	The neurobiology of vascular head pain. <i>Annals of Neurology</i> , 1984 , 16, 157-68	9.4	769
3	Protein synthesis in rat brain microvessels decreases with aging. <i>Journal of Neurochemistry</i> , 1981 , 36, 1311-5	6	16
2	Dihydropteridine Reductase Deficiency Associated With Severe Neurologic Disease and Mild Hyperphenylalaninemia. <i>Pediatrics</i> , 1979 , 63, 94-99	7.4	30
1	Therapeutic Management: When and What		2